Limited's (NYSEAMERICAN:VNRX) Reynolds caught up with Proactive London's Andrew Scott to discuss the group's second quarter update.
Reynolds says they've continued to strengthen the balance sheet with cash and cash equivalents increasing significantly thanks to warrant exercises by investors.
He adds they're now looking to advance the previously announced large-scale colorectal cancer trials in Europe, the US and Asia as well as the clinical trial program for lung cancer.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE